Navoximod

Drug Profile

Navoximod

Alternative Names: GDC-0919; NLG-919; RG-6078

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer Chugai Pharmaceutical; Genentech; NewLink Genetics Corporation
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Immunomodulators; Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 27 Jul 2017 Discontinued - Phase-I for Solid tumours (Combination therapy, Late-stage disease) in Japan (PO) (Chugai Pharmaceutical pipeline, July 2017)
  • 27 Jul 2017 Discontinued - Phase-I for Solid tumours (Late-stage disease, Monotherapy) in Japan (PO) (Chugai Pharmaceutical pipeline, July 2017)
  • 08 Jun 2017 Genentech plans to terminate the license for navoximod
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top